Mineralys Therapeutics (MLYS) Stock Forecast, Price Target & Predictions
MLYS Stock Forecast
Mineralys Therapeutics stock forecast is as follows: an average price target of $30.00 (represents a 155.10% upside from MLYS’s last price of $11.76) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
MLYS Price Target
The average price target for Mineralys Therapeutics (MLYS) is $30.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential 155.10% upside from MLYS's last price of $11.76.
MLYS Analyst Ratings
According to 2 Wall Street analysts, Mineralys Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MLYS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Mineralys Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 02, 2024 | Richard Law | Goldman Sachs | $30.00 | $13.03 | 130.24% | 155.10% |
The latest Mineralys Therapeutics stock forecast, released on Apr 02, 2024 by Richard Law from Goldman Sachs, set a price target of $30.00, which represents a 130.24% increase from the stock price at the time of the forecast ($13.03), and a 155.10% increase from MLYS last price ($11.76).
Mineralys Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $30.00 |
| Last Closing Price | $11.76 | $11.76 | $11.76 |
| Upside/Downside | -100.00% | -100.00% | 155.10% |
In the current month, the average price target of Mineralys Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mineralys Therapeutics's last price of $11.76. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 10, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Apr 02, 2024 | Goldman Sachs | - | Buy | Initialise |
Mineralys Therapeutics's last stock rating was published by H.C. Wainwright on Jul 10, 2024. The company Initialise its MLYS rating from "null" to "Buy".
Mineralys Therapeutics Financial Forecast
Mineralys Therapeutics Revenue Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Mineralys Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MLYS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Mineralys Therapeutics EBITDA Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
undefined analysts predict MLYS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mineralys Therapeutics's previous annual EBITDA (undefined) of $NaN.
Mineralys Therapeutics Net Income Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - |
| Avg Forecast | $-178.86M | $-40.47M | $-41.46M | $-44.42M | $-42.61M | $-34.55M |
| High Forecast | $-178.86M | $-40.47M | $-41.46M | $-44.42M | $-41.07M | $-34.55M |
| Low Forecast | $-178.86M | $-40.47M | $-41.46M | $-44.42M | $-43.64M | $-34.55M |
| Surprise % | - | - | - | - | - | - |
Mineralys Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MLYS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Mineralys Therapeutics SG&A Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Mineralys Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MLYS last annual SG&A of $NaN (undefined).
Mineralys Therapeutics EPS Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - |
| Avg Forecast | $-3.62 | $-0.82 | $-0.84 | $-0.90 | $-0.86 | $-0.70 |
| High Forecast | $-3.62 | $-0.82 | $-0.84 | $-0.90 | $-0.83 | $-0.70 |
| Low Forecast | $-3.62 | $-0.82 | $-0.84 | $-0.90 | $-0.88 | $-0.70 |
| Surprise % | - | - | - | - | - | - |
According to undefined Wall Street analysts, Mineralys Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MLYS previous annual EPS of $NaN (undefined).
MLYS Forecast FAQ
Is Mineralys Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Mineralys Therapeutics (MLYS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of MLYS's total ratings.
What is MLYS's price target?
Mineralys Therapeutics (MLYS) average price target is $30 with a range of $30 to $30, implying a 155.10% from its last price of $11.76. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Mineralys Therapeutics stock go up soon?
According to Wall Street analysts' prediction for MLYS stock, the company can go up by 155.10% (from the last price of $11.76 to the average price target of $30), up by 155.10% based on the highest stock price target, and up by 155.10% based on the lowest stock price target.
Can Mineralys Therapeutics stock reach $20?
MLYS's average twelve months analyst stock price target of $30 supports the claim that Mineralys Therapeutics can reach $20 in the near future.
What are Mineralys Therapeutics's analysts' financial forecasts?
MLYS's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-122M (high $-120M, low $-123M), average SG&A $0 (high $0, low $0), and average EPS is $-2.463 (high $-2.432, low $-2.484).